RxDoctor Payments Data

Vicki Haines

Nurse Practitioner · Pasco, WANPI 1720386808

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $38,320 of the $56,811 with a category attached, or 67.5%. 29 manufacturers reported payments, led by AbbVie at 35.8% of the total. 2025 is the largest year on record at $19,169, 2.2 times the $8,768 reported in 2021. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,811in general payments, 2019–2025

Across 861 payments — averaging $65.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$20K
  • Johnson & Johnson$6K
  • Lilly USA, LLC$5K
  • Sun Pharmaceutical Industries Inc.$4K
  • Regeneron Healthcare Solutions, Inc.$4K
  • UCB, Inc.$4K
  • plus $13K from 23 others

What the payments were for

  • Consulting fees$3,3396%
  • Speaking & faculty fees$38,32067%
  • Travel & lodging$30%
  • Food & beverage$14,32425%
  • Education$8261%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,811 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$494,194
Medicare patients
806
Services billed
9,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa28$620,251
Cosentyx Unoready PenSecukinumab36$382,430
Humira(Cf) PenAdalimumab32$309,084
Dupixent PenDupilumab71$297,842
Cosentyx Sensoready (2 Pens)Secukinumab22$180,077
Dupixent SyringeDupilumab11$47,842
Triamcinolone Acetonide284$3,789
Tacrolimus29$3,591
Clobetasol Propionate84$3,513
Nystatin94$1,399
MethotrexateMethotrexate Sodium121$1,274
Doxycycline Hyclate31$730
Doxycycline Monohydrate18$714
Fluconazole38$671
Clindamycin Phosphate17$450

Paid to pharmacies, not to this prescriber.

Other nurse practitioner in Pasco

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →